Drug interactions
Deferasirox + Tucatinib
Severity: Moderate
Deferasirox and Tucatinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Tucatinib is partly metabolized by CYP2C8, and deferasirox is a CYP2C8 inhibitor. Co-use may increase tucatinib levels and the risk of diarrhea and hepatotoxicity.
What this interaction means in plain words
Deferasirox and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Deferasirox belongs to Miscellaneous; Tucatinib belongs to Oncology.
Why it happens
Deferasirox inhibits CYP2C8, reducing tucatinib metabolism.
What to do
Avoid the combination if possible. If used, monitor liver enzymes and diarrhea, and reduce the tucatinib dose if toxicity occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Deferasirox and Tucatinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Deferasirox
Other interactions of Tucatinib
- Cisapride + Tucatinib Contraindicated
- Eletriptan + Tucatinib Contraindicated
- Ergotamine + Tucatinib Contraindicated
- Flibanserin + Tucatinib Contraindicated
- Ranolazine + Tucatinib Contraindicated
- Amobarbital + Tucatinib Major
Frequently asked questions
Can I take Deferasirox with Tucatinib?
MediHelp rates the interaction as moderate. Deferasirox and Tucatinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Tucatinib is partly metabolized by CYP2C8, and deferasirox is a CYP2C8 inhibitor. Co-use may increase tucatinib levels and the risk of diarrhea and hepatotoxicity.
How serious is the interaction between Deferasirox and Tucatinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination if possible. If used, monitor liver enzymes and diarrhea, and reduce the tucatinib dose if toxicity occurs.
What other medicines interact with Deferasirox?
MediHelp also lists interactions of Deferasirox with, for example, Acetylsalicylic acid, Alosetron, Aluminum hydroxide. The full list is on the Deferasirox page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
